Endotoxinemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress by Zampino, Rosa et al.
Vol.:(0123456789) 
Infection 
https://doi.org/10.1007/s15010-018-1185-6
ORIGINAL PAPER
Endotoxinemia contributes to steatosis, insulin resistance 
and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory 
cytokines and oxidative stress
Rosa Zampino1 · Aldo Marrone1 · Luca Rinaldi1 · Barbara Guerrera1 · Riccardo Nevola1 · Adriana Boemio1 · 
Natalina Iuliano1 · Mauro Giordano1 · Nicola Passariello1 · Ferdinando C. Sasso1 · Emanuele Albano2 · 
Luigi E. Adinolfi1
Received: 7 April 2018 / Accepted: 27 July 2018 
© Springer-Verlag GmbH Germany, part of Springer Nature 2018
Abstract
Purpose Endotoxin is a component of the outer membrane of gram-negative bacteria that live in the intestine. Endotoxine-
mia is reported in non-alcoholic fatty liver disease and in cirrhotic patients, causing various biological and clinical effects 
in the host. It is not known whether endotoxinemia occurs in chronic hepatitis C patients (CHC), therefore we evaluated 
the occurrence of endotoxinemia and its effect on inflammation, liver damage, insulin resistance (IR) and atherosclerosis.
Methods Consecutive CHC patients assessed by liver biopsy were enrolled. Endotoxinemia was evaluated by LAL test. 
IR was estimated by HOMA-IR. Serum TNF-α, IL-8, adiponectin and MCP-1 were measured with ELISA tests. Oxidative 
stress was estimated by circulating IgG against malondialdehyde adducts with human serum albumin (MDA-HAS). Carotid 
atherosclerosis was assessed by ultrasonography.
Results Endotoxinemia was found in 60% of the 126 patients enrolled. A serum level-dependent association between endo-
toxinemia, steatosis (p < 0.001) and HOMA-IR (p < 0.006) was observed. Patients with endotoxinemia showed significant 
increase in TNF-α and IL8 levels. TNF-α correlated with steatosis (p <  0.001) and HOMA-IR (p < 0.03), whereas IL8 cor-
related with steatosis (p =  <0.001), TNF-α (p < 0.04) and atherosclerosis (p < 0.01). The highest levels of endotoxinemia were 
associated with oxidative stress and a higher prevalence of carotid atherosclerosis. Multivariate logistic regression analysis 
showed that the independent factors associated with endotoxinemia were hepatic steatosis, HOMA-IR, IL8 and MDA-HAS.
Conclusions Endotoxinemia occurs with high frequency in CHC patients and contributes to the development of hepatic 
steatosis, IR and atherosclerosis through increased pro-inflammatory cytokines and oxidative stress. Anti-endotoxin treat-
ment could be of clinical relevance.
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Introduction
Endotoxin or lipopolysaccharides (LPS) is a component 
of the outer membrane of gram-negative bacteria and the 
intestine is a large pool of LPS in the body. A small amount 
of LPS can escape from the intestine and through the por-
tal vein reach the liver where it is cleared from the reticu-
loendothelial system (RES), avoiding a spillover into the 
systemic circulation. However, endotoxinemia can occur in 
various clinical conditions such as chronic hepatitis, cirrho-
sis, non-alcoholic fatty liver disease (NAFLD) and obesity. 
Endotoxinemia is known to induce various biological effects 
in the host involving the liver, cardiovascular, metabolic and 
neurologic systems [1].
In cirrhotic patients, endotoxinemia may be the result of 
a decrease in the phagocytic capacity of the liver, a leakage 
through portosystemic shunts and an increased adsorption 
of endotoxin due to amplified intestinal permeability [2, 3]. 
However, irrespective of cirrhosis, endotoxinemia may be a 
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consequence of a high-fat diet intake either through direct 
diffusion via intestinal paracellular permeability or through 
absorption by enterocytes during the secretion of chylomi-
cron [4], as well as the result of excessive intestinal produc-
tion by an altered microbiota.
Human studies have shown that endotoxinemia occurs in 
both adult and pediatric patients with NALFD [5, 6], pro-
moting an increase in the serum TNF-α level that aggra-
vates insulin resistance (IR) and liver steatosis [7], and it 
is claimed that this condition can promote weight gain, the 
development of NASH, type 2 diabetes mellitus (T2DM) 
and atherosclerosis [8].
Liver steatosis and IR are features of chronic hepatitis C 
infection [9] and are of clinical relevance both in the pro-
gression of liver injury and in the development of extrahe-
patic manifestations [10] and, in particular, T2DM and ath-
erosclerosis [11]. Therefore, it is of clinical and therapeutic 
interest to know whether endotoxinemia is a condition that 
occurs in chronic hepatitis C and whether it may have a role 
in the development of HCV-associated conditions such as 
steatosis, IR, chronic inflammation and atherosclerosis.
Accordingly, the aim of this study was to assess in a series 
of consecutive patients with liver biopsy proven chronic 
hepatitis C the prevalence and effects of endotoxinemia and 
its role in: (a) the progression of hepatic histological dam-
age (steatosis, necroinflammatory activity, fibrosis), (b) the 
development of IR, (c) the production of pro-inflammatory 
cytokines, oxidative stress and chemokines and, (d) the 
development of atherosclerosis.
Materials and methods
Patients
Consecutive treatment-naïve chronic hepatitis C patients 
who underwent liver biopsy for diagnostic purposes were 
enrolled in this study. Patients with the following conditions 
were excluded from the study: co-infection with HBV or 
HIV, alcohol intake greater than 20 g/day, active drug user 
and with severe comorbidities such as cardiac, pulmonary, 
renal, rheumatologic, autoimmune and inflammatory gastro-
intestinal diseases. None of the patients received steatogenic 
drugs, antibiotics or probiotics. Patients with urinary tract 
infection or sepsis as evaluated by urine and blood culture 
and in general subjects with fever were not included in the 
study.
At the time of the liver biopsy, a liver ultrasound scan 
was performed, epidemiological and demographic data were 
obtained and BMI (kg/m2) was calculated for all patients. 
At that time, serum samples were obtained and stored at 
− 70 °C in pyrogen-free vials and in all patients, hepatic 
and renal biochemical tests and blood cells count were 
determined.
Patients were assessed for carotid intima-media thick-
ness (IMT) using high-resolution B-mode ultrasonography 
(Esaote Techos, Genova, Italy) equipped with a 7.5 MHz 
linear-array transducer as previously described [10]. 
IMT > 1 mm was regarded as a cut-off value for carotid ath-
erosclerosis (CA). Plaque was defined as a protrusion in the 
lumen of the vessel of at least 1.5 mm, as measured from the 
border between the adventitia and median layers.
All patients signed an informed consent and the study 
protocol in accordance with the ethical guidelines of the 
1975 Helsinki Declaration was approved by the Local Eth-
ics Committee.
Viral markers
The anti-HCV antibodies were tested by ELISA (Abbott 
Laboratories, Chicago, IL) and HCV RNA was tested 
by PCR assay (Amplicor HCV; Roche Diagnostic SpA). 
HCV RNA serum levels were measured by real-time PCR 
(Taqman, Applied BioSystems). HCV genotyping was per-
formed using a reverse hybridization line probe assay (INNO 
LiPA HCV assay, 2nd generation, Innogenetics, Zwijndrecht, 
Belgium) following the manufacturer’s protocol.
Hepatitis B markers and HIV antibodies were assayed 
using commercially available ELISA tests.
Histology evaluation
Liver histology was evaluated on liver tissue > 1.5  cm 
through formalin-fixation, followed by paraffin embedment 
and staining with hematoxylin–eosin, trichrome and Prus-
sia blue. “Grading” and “staging” were assessed separately, 
according to Ishak et al [12]. Different scores were assigned 
to different levels of steatosis: 0, < 5% of steatosis; 1, 5–10% 
of hepatocytes with steatosis; 2, 11–30%; 3, 31–60%; 4, 
> 60% of hepatocytes with steatosis.
Endotoxinemia
Quantification of serum LPS was obtained by Limulus Ame-
bocyte Lysate (LAL) with end-point chromogenic method 
(LAL test, Cape Cod Incorporated/PBI). The cut-off of the 
test for positivity was calculated using a mean value of 30 
healthy controls plus 2 times the standard deviation and was 
fixed at 0.78 UE/ml.
Insulin resistance
Serum insulin levels were assayed with a radioimmunoassay 
method (Insulin RIA DSL-1600, Diagnostic System Labo-
ratories, USA). The intra- and inter-assay coefficients of 
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variation ranged from 4.5 to 8.3% and from 4.7 to 12.2%, 
respectively. The percentages of insulin recovery in analyzed 
samples ranged from 92 to 119%. In each subject, the degree 
of insulin resistance was estimated by HOMA-IR using the 
following formula: [fasting plasma glucose (mmol/L) x fast-
ing serum insulin (mIU/L)]/22.5.
Cytokines and chemokines
Serum TNF-α and IL-8 were measured by ELISA test, using 
the Human ELISA kit (Pierce Biotechnology, Rockford, IL); 
serum adiponectin levels using the Human Adiponectin 
ELISA kit (B-Bridge International, Osaka, Japan); MCP-1 
was measured using a Human MCP-1 ELISA Kit (Thermo 
Scientific™ Pierce™).
Measurement of the antibody titers against lipid 
peroxidation‑derived antigens
Oxidative stress was measured by circulating IgG against 
malondialdehyde adducts with human serum albumin 
(MDA-HSA) in HCV-infected patients and in 70 healthy 
controls. Serum human albumin (HSA) adducts with malon-
dialdehyde (MDA) were prepared as previously described 
[13]. The enzyme-linked immunosorbent assay (ELISA) 
was performed with patient’s serum as previously reported 
[13]. The results were expressed by subtracting the back-
ground reactivity observed with unmodified HSA. Immu-
nological evidence of oxidative stress was considered when 
the value of anti-MDA-HSA IgG levels exceeded the 95th 
percentile of the control group (median value, o.d. 490 nm, 
0.126 ± 0.052).
Statistical analysis
Values are expressed as the mean ± standard deviation (SD) 
or median and range. The mean differences between the 
cases and controls were evaluated by the Student’s t test 
for parametric data. The Mann–Whitney U test was used 
to compare non-parametric data between groups. The Chi 
square test was used to test differences between proportions. 
Spearman correlation was used to evaluate the association 
between endotoxin and other variables such as age, sex, 
BMI, visceral obesity, glycaemia, HOMA-IR, HCV geno-
type, serum HCV RNA levels, TNF-α, IL8, adiponectin, 
MCP-1, hepatic steatosis, HAI, fibrosis and atherosclerosis. 
The variables significantly associated at univariate analysis 
were evaluated in the multivariate analysis using a logis-
tic regression analysis model. Statistical analysis was per-
formed using the SPSS software for Windows (Version 17.0) 
(Chicago, IL, USA) and a p value < 0.05 was considered 
significant.
Results
Patient’s characteristics and prevalence 
of endotoxinemia
One hundred and twenty-six consecutive chronic hepatitis 
C patients who underwent liver biopsy were enrolled in this 
study. Eight patients (6% of the entire eligible population) 
were not included in the study for one of the aforementioned 
causes. The median age was 55 years (range 18–68 years), 
males were 56%, steatosis was present in 54%, cirrhosis in 
10% and type 2 diabetes in 10.3% of cases. Carotid ath-
erosclerosis was present in 49.2% of patients. Endotox-
inemia was found in 76 (60%) patients. Serum anti-MDA-
HAS IgG leels, as a marker of oxidative stress-mediated 
responses, were significantly higher in CHC patients than in 
healthy controls (o.d 490 nm: 0.228 ± 0.10 vs 0.126 ± 0.052; 
p < 0.001, respectively) and the overall prevalence of CHC 
patients with immunological evidence of oxidative stress 
(anti-MDA-HSA IgG levels above the 95th percentile of the 
control group) was 59%. Table 1 shows the characteristics 
of patients in relation to the presence or absence of serum 
endotoxin.
Endotoxinemia, steatosis and IR
Data showed that patients with endotoxinemia had signifi-
cantly higher levels of steatosis (p < 0.01; Table 1). Simi-
larly, a significant difference between the two groups was 
present for HOMA-IR (p = 0.05). Such differences were 
irrespective of type 2 diabetes and/or cirrhosis (data not 
shown). The correlation test showed a significant associa-
tion between LAL and steatosis (r = 0.475; p < 0.001) and 
HOMA-IR (r = 0.025; p < 0.006).
Considering that the endotoxin effects are reported to be 
dose-dependent [2], an analysis based on the different serum 
endotoxin levels was performed. Table 2 shows the analysis 
of quartile-based data of endotoxinemia and shows a statisti-
cally significant difference between the first and fourth quar-
tile in steatosis score (p = 0.001), and HOMA-IR (p = 0.001).
Endotoxinemia, inflammatory cytokines 
and oxidative stress
Endotoxinemia was associated with increased systemic 
inflammation as indicated by higher levels of TNF-α 
and IL8, whereas it was not correlated with MCP-1 lev-
els (Table 1). Table 2 shows the levels of cytokines in 
relation to quartile endoxinemia levels. The data showed 
an increase in serum TNF-α and IL8 levels with the pro-
gressive increase in endotoxin levels. Circulating IL8 
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correlated with steatosis (r = 0.632, p = 0.001), LAL 
(r = 0.681, p = 0.001) and TNF-α (r = 531, p = 0.042), 
whereas serum TNF-α levels correlated also with stea-
tosis (r = 0.291; p < 0.001) and HOMA-IR (r = 0.129; 
p < 0.029). On the contrary, MCP-1 was not associated 
with any of the parameters evaluated, regardless of the 
levels of endotoxinemia. The highest levels of endotox-
inemia were also associated with a significant increase in 
anti-MDA IgG levels (Table 2), indicating that high levels 
of endotoxinemia are associated with oxidative stress.
Endotoxinemia as a risk factor of atherosclerosis
Chronic HCV infection is known to be associated with ather-
osclerosis [11]. In this context, a pro-inflammatory environ-
ment and oxidative stress was proposed to play an important 
role in explaining this association [14, 15]. Therefore, based 
on the aforementioned data, we investigated the possible 
role of endotoxinemia in modulating the risk of atheroscle-
rosis among HCV patients. The overall prevalence of ath-
erosclerosis (increased IMT plus plaque) was no different 
Table 1  Characteristics of 
the patients according to 
the presence or absence of 
endotoxinemia
+ IMT increased plus plaque; *Student’s t test ; **Mann–Whitney U test
Variables Endotoxemia
Absent < 0.78 EU/ml Present > 0.78 EU/ml p
No. of patients 50 (40%) 76 (60%)
Age, median (range) 53 (20–68) 55 (18–64) Ns
Male (%) 25 (50%) 46 (60%) Ns
ALT U/L, median (range) 88 (46–461) 93.5 (40–433) Ns
HCV RNA, UI/ml ×  105 median (range) 4.43 (0.8–56) 7.42 (0.1–32) Ns
Cholesterol mg/dl, mean ± SD 173 ± 36 175 ± 39 Ns
Triglycerides mg/dl, mean ± SD 115 ± 107 103 ± 40 Ns
Glucose mg/dl, median (range) 93 (68–159) 93 (71–201) Ns
Insulin μU/ml, median (range) 20.9 (6.5–47.8) 22.9 (6.4–96.4) Ns
HOMA-IR, mean ± SD 4.3 ± 2.6 5.5 ± 2.9 0.05*
Type 2 diabetes 10% 11.4% Ns
TNFα pg/ml, median (range) 12.0 (2.5–25) 51 (6.25–736) 0.016**
ADP, U/L median (range) 9.94 (3–12) 8.24 (2.6–26) Ns
Serum IL8, (pg/ml), mean ± s.d 10.46 ± 3.7 24.02 ± 19.8 0.001**
Serum MCP-1, (pg/ml), mean ± s.d 142.34 ± 39 149.15 ± 42 Ns
MDA, mean ± SD 0.21 ± 0.08 0.24 ± 0.12 Ns
Steatosis score, mean ± s.d 1.2 ± 1.2 2.1 ± 1.4 0.01
HAI score, median (range) 6.0 (1–11) 6.2 (1–13) Ns
Fibrosis score, mean ± s.d 2.6 ± 1.1 2.6 ± 1.2 Ns
Cirrhosis 12% 10% Ns
Prevalence of carotid atherosclerosis+ 48% 54.2% Ns
Table 2  Distribution of variables according to the quartiles of endotoxinemia values as evaluated by the LAL test
*Quartile 4 vs quartile 1
+ Quartiles 2–4 vs 1
Quartiles 1st 2nd 3rd 4th p
Serum LPS concentration < 0.60 EU/l 0.61–1.20 EU/l 1.21–2.20 EU/l > 2.20 EU/l
Steatosis score mean ± SD 0.8 ± 1.1 1.6 ± 1.5 2.0 ± 1.4 2,4 ± 1.2* 0.001
HOMA-IR mean ± SD 3.9 ± 2.3 4.38 ± 3,3 4.76 ± 1.93 6.37 ± 3.2* 0.005
TNF—pg/ml median (range) 10.9 (2.5–25) 13 (2.6–525) 25.5 (6.2–497) 90.7 (6-736)* 0.03
Serum IL8 (pg/ml) mean ± SD 10.7 ± 3.7 M 26.1 ± 19.1 M 24.3 ± 8.1 29.5 ± 22.6 0.001+
Serum MCP-1 (pg/ml) mean ± SD 130.9 ± 37 M 153.4 ± 59.7 M 144 ± 47.7 157 ± 42.2 Ns
MDA mean ± SD 0.20 ± 0.77 0.19 ± 0.07 0.20 ± 0.07 0.26 ± 0.12* 0.025
HAI score median (range) 5 (1–11) 5 (1–10) 6 (1–13) 6 (1–13) Ns
Fibrosis score mean ± SD 2.3 ± 1.1 2.4 ± 1.2 2.4 ± 1.1 2.5 ± 1.3 Ns
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between patients with and without endotoxinemia (Table 1). 
However, as shown in Table 3, when the data were analyzed 
using the median value of endotoxinemia as cut-off, a higher 
prevalence of both increased IMT and plaque were observed 
in the third and fourth quartiles compared to that observed in 
the first and second quartiles (p < 0.002). A correlation was 
also found between IL8 and the presence of atherosclerosis 
(r = 0.34, p < 0.01).
Factors independently associated 
with endotoxinemia
An overall analysis of the variable independently associated 
to the serum endotoxin was evaluated in the multivariate 
logistic regression model and showed that hepatic steatosis 
and IL8 were independently associated with endotoxine-
mia. However, as seen in Table 4, when the analysis was 
performed using the highest serum endotoxin levels (4th 
quartiles), HOMA-IR and MDA also became independent 
variables.
Discussion
In this study we have shown that, regardless of liver cir-
rhosis, endotoxinemia is a condition that occurs with 
high frequency (60%) in our series of chronic hepatitis C 
patients and that patients with endotoxinemia, especially 
those with the highest serum LPS concentrations showed 
significantly higher levels of pro-inflammatory cytokines 
and oxidative stress and a significant association with 
higher levels of hepatic steatosis, IR and prevalence of 
atherosclerosis. These data support the concept that by 
increasing the levels of pro-inflammatory cytokines and 
oxidative stress, endotoxinemia contributes to the develop-
ment of hepatic and extrahepatic manifestations associated 
with HCV such as fatty liver, IR and atherosclerosis.
In experimental models, LPS has been shown to play 
a role in the increase of IR, hepatic steatosis and inflam-
mation [16]. Most of the biological effects of LPS have 
been related to the release of pro-inflammatory cytokines, 
such as TNF-α, interleukins (IL-1, IL-6, IL-8 and IL-12), 
chemokines (MPC-1) and oxidative stress [17]. Kupffer’s 
liver cells, through their receptors for LPS, toll-like recep-
tors (TLRs), are the primary cells involved in the LPS 
response producing inflammatory cytokines [18]. TNF-α, 
which is the main cytokine induced by LPS-TLR4, is rec-
ognized as the main mediator of hepatotoxicity, inflamma-
tion and development of IR and steatosis [19].
Endotoxinemia has been reported in patients with 
NAFLD [5, 6], promoting the development of NASH and 
a worsening of IR [8]. These effects are at least partly 
related to the increase in intestinal permeability [20], 
with subsequent translocation of LPS into the portal vein, 
activating the inflammatory phenotype of Kupffer cells 
[21] and promoting an inflammatory response [22, 23]. In 
particular, among the mediators of inflammation (adipocy-
tokines), TNFα plays an important role in the pathogenesis 
of NAFLD/NASH and IR [24, 25].
The role of the imbalance between TNF-α and adi-
ponectin is known in the pathogenesis of IR in chronic 
hepatitis C [26, 27], and the release of free fatty acids 
from peripheral sites to the liver could be a fascinating 
hypothetical mechanism contributing to steatosis and IR 
development in chronic hepatitis C. Furthermore, it has 
been shown that endotoxin, associated with HCV core pro-
tein, is able to promote inflammation in chronic hepatitis 
C by activating monocyte/macrophage [28].
Our study showed that endotoxinemia occurs with high 
frequency in chronic hepatitis C patients and is level-
dependent associated with increased levels of TNF-α, 
which, in turn, contribute to the development of IR and 
fatty liver deposition. In this study, we were unable to 
demonstrate an increase in necroinflammatory damage and 
hepatic fibrosis associated with endotoxinemia. However, 
in previous experimental and clinical studies, the presence 
of endotoxinemia has been associated with an increase 
in necroinflammatory hepatic activity and at an advanced 
stage of liver disease [2, 21, 29]. Moreover, considering 
that the role of hepatic steatosis and IR is well-known in 
the progression of liver disease leading to fibrosis [9], it 
is therefore possible that endotoxin, modulating steatosis 
and IR, may contribute to the development of liver fibrosis 
and type 2 diabetes in the long term.
Table 3  Prevalence of atherosclerosis (increased IMT or plaque) 
according to the median value of endotoxinemia
Endotoxineamia
< 1.21 UE/l (%) > 1.21 UE/l (%) p
Increased IMT 56.5 70.0
Plaque 17.4 40.0 0.002
Table 4  Independent factors associated with all endotoxinemia using 
all values* or using the highest values of serum endotoxinemia levels 
(4th quartile) **
Coefficient B std. 
error
95% CI p
Lower Higher
Steatosis* 0.243 0.082 0.080 0.406 0.004
IL8* 0.124 0.064 0.042 0.628 0.022
Homa-IR** 0.030 0.015 0.001 0.059 0.046
MDA** 0.272 0.102 0.069 0.475 0.001
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Among the biological responses of endotoxinemia, oxi-
dative stress is one of the significant effects implicated in 
hepatic, cardiovascular and metabolic damage [30]. Oxida-
tive stress is a condition observed with high frequency in 
chronic hepatitis C and contributes to the development and 
progression of liver injury as well as liver in the fat deposi-
tion, IR and cardiovascular damage [9, 13, 31]. Data from 
this study showed that HCV patients with the highest levels 
of endotoxinemia showed an increase in levels of MDA-
HAS as an expression of chronic oxidative stress. Therefore, 
by causing oxidative stress, endotoxinemia contributes to 
the hepatic and metabolic damage associated with chronic 
hepatitis C and in particular steatosis, IR and cardiovascular 
damage.
Atherosclerosis is known to be associated with chronic 
HCV infection [11] and both direct and indirect mechanisms 
have been proposed [32]. Among the indirect mechanisms, 
a pro-inflammatory environment has been reported in which 
pro-inflammatory cytokines and oxidative stress play an 
important role [15]. LPS through TLR4 has been reported as 
one of the triggers of the inflammatory pathway in the gen-
eration of atherosclerosis [33]. Furthermore, oxidative stress 
contributes to the inflammatory and metabolic processes that 
generate and maintain atherosclerosis [34, 35]. In this study, 
patients with a significant amount of endotoxinemia showed 
a higher prevalence of carotid atherosclerosis in associa-
tion with pro-atherogenic conditions such as hepatic stea-
tosis, IR, oxidative stress and pro-inflammatory cytokines. 
Among the latter, in addition to TNF-α, we demonstrated a 
significant increase in IL-8 but not MPC-1. IL-8 is mainly 
monocyte and macrophage secreted and its main effect is 
the recruitment and activation of monocytes and neutrophils 
in an acute site of inflammation [36]. Furthermore, IL-8 is 
involved in the regulation of the oxidant gene expression and 
is highly sensitive to oxidants [37]. The role of oxidants in 
the regulation of IL-8 and other chemokines has relevance 
in the field of cardiovascular disease [38]. There is a body 
of evidence that IL-8 plays an important role in atheroscle-
rosis [38]. IL-8 is involved in the adhesion phase of mono-
cytes in the early stages of atherosclerosis [39], but it plays 
a role also in the advanced phase of atherosclerosis [40]. 
Furthermore, LPS is known to release the pro-inflammatory 
cytokine IL8 from monocytes. Data from our study indi-
cate that in chronic hepatitis C patients, significant levels of 
endotoxinemia contribute to the development of atheroscle-
rosis through increased IL8 secretion as well as by oxidative 
stress, steatosis and IR.
Treatment with direct antiviral agents (DAAs) against 
HCV is now able to achieve a sustained virological response 
(SVR) in more than 95% of patients treated; however, histo-
logical liver damage and systemic involvement remain and 
will probably diminish only over the years. Under experi-
mental and clinical conditions, a decrease in endotoxinemia 
levels by antibiotic or probiotic treatment has been shown to 
lead to improvement of the associated conditions [41]. Thus, 
anti-endotoxin treatment in chronic hepatitis C patients with 
endotoxinemia could be valuable for improving steatosis, IR 
and atherosclerosis.
In conclusion, the data from this study indicate that endo-
toxinemia in chronic hepatitis C occurs with high frequency 
and is of clinical relevance, influencing, with cross-reaction 
mechanisms, IR, systemic inflammation, oxidative stress, 
hepatic steatosis and atherosclerosis. Control of serum 
endotoxin levels could be useful also in patients with SVR 
by DAA, slowing the progression of hepatic and extrahe-
patic manifestations and perhaps improving their long-term 
prognosis.
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